RBD-SpyVLP
A candidate COVID-19 subunit vaccine.
General information
RBD-SpyVLP is an experimental protein subunit vaccine based on SARS-CoV2 Spike protein receptor binding domain (RBD) assembled on a protein nanoparticle platform (SpyCatchet003-mi3). It retains stability and immunogenicity (in mice and pigs) after lyophilisation (Tan et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Spike protein Animal model Mixed substance |
C57BL/6 mice; BALB/c mice; pigs; SARS-CoV-2 strain hCoV-19/England/02/2020, EPI_ISL407073; SARS-CoV-2 strain hCoV-19/VIC01/2020 (GenBank MT007544) | 12.12 | The protein subunit vaccine assembly was efficient and the tested antibodies (anti-RBD) and dimeric ACE2-Fc all bound it in vitro. The vaccine retained its functionality after repeated freeze-thaw cycles or lyophilization. Mice which were intramuscularly primed and boosted with the AddaVax-adjuvanted vaccine displayed high titres of anti-RBD, anti-Spike, and neutralizing antibodies. The sera of the immunized mice potently blocked ACE2 in vitro. Strong immunogenic and neutralising antibody responses were observed in pigs, as well. The anti-RBD antibody responses in mice and pigs were polyclonal and remained neutralising in pigs for at least two months. |
Jan/22/2021 |
